Keynote Presentation: Has the cannabis testing industry reached an impasse? or is something else going on?

Over the past decade, cannabis testing has evolved from a niche laboratory service into one of the most heavily scrutinized and operationally complex sectors in the regulated cannabis economy. At first glance, the  industry appears to be at an impasse: fragmented state-by-state rules, inconsistent enforcement, escalating testing requirements, and persistent concerns about potency inflation have created a system that feels strained, unstable, and scientifically uneven. But this keynote challenges that assumption. The pressures facing cannabis testing are not signs of stagnation — they are indicators of a deeper structural transition.

This presentation reframes the narrative by examining the regulatory, scientific, and economic forces that have shaped the industry from 2014 to 2026. It explores how rapid policy expansion, shifting definitions of hemp and intoxicating cannabinoids, and the absence of national standards have produced a landscape where laboratories must constantly adapt, revalidate, and rebuild. At the same time, it highlights the emergence of new harmonization efforts, advances in instrumentation and automation, and a growing demand for pharmaceutical-grade data integrity.

Learning Objectives:

1. Understand the structural forces that shaped cannabis testing from 2014 - 2026

2. Recognize the root causes of inconstistency, instability, and market distortion in laboratory testing.

3. Evaluate whether the industry is truly at an impasse or entering a pivotal transition toward modernization